These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7863424)

  • 1. [Tamoxifen and osteoporosis].
    Dunst J
    Strahlenther Onkol; 1995 Feb; 171(2):113-4. PubMed ID: 7863424
    [No Abstract]   [Full Text] [Related]  

  • 2. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for prevention of breast cancer.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
    [No Abstract]   [Full Text] [Related]  

  • 4. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM; Martino S
    Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two large RCTs fail to demonstrate any benefit of bisphosphonates in breast cancer.
    Brown S
    Post Reprod Health; 2014 Dec; 20(4):130. PubMed ID: 25621340
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogens and osteoporosis.
    Ribot C; Trémollières F
    Rev Rhum Engl Ed; 1998 Nov; 65(11):641-8. PubMed ID: 9850533
    [No Abstract]   [Full Text] [Related]  

  • 13. [New, pioneering PTH treatment of postmenopausal osteoporosis. Quick effect on bone density and bone formation].
    Törring O
    Lakartidningen; 2001 Oct; 98(42):4552-3. PubMed ID: 11715225
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?
    Ding H; Field TS
    Cancer Treat Rev; 2007 Oct; 33(6):506-13. PubMed ID: 17573199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
    Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alendronate also for women without established osteoporosis?].
    Klovning A; Norheim OF
    Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1347-51. PubMed ID: 10868100
    [No Abstract]   [Full Text] [Related]  

  • 17. [Selected estrogen receptor modulators--new possibilities in prevention and therapy of osteoporosis?].
    Dören M
    Med Klin (Munich); 1996 Feb; 91 Suppl 1():44-5. PubMed ID: 8839116
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.